Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus

Benzinga11-15

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Friday shared initial data from the ongoing Phase 2 open-label trial of Descartes-08, its lead cell therapy candidate, for systemic lupus erythematosus (...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583685787?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/14/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2025-11-15 02:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583685787","market":"us","top_or_hot":-1,"title":"Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus","media":"Benzinga","content":"<div>\n<p>Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Friday shared initial data from the ongoing Phase 2 open-label trial of Descartes-08, its lead cell therapy candidate, for systemic lupus erythematosus (...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/11/48873824/cartesian-pauses-lupus-and-multiple-myeloma-studies-as-it-shifts-development-focus\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-15 02:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/25/11/48873824/cartesian-pauses-lupus-and-multiple-myeloma-studies-as-it-shifts-development-focus><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Friday shared initial data from the ongoing Phase 2 open-label trial of Descartes-08, its lead cell therapy candidate, for systemic lupus erythematosus (...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/11/48873824/cartesian-pauses-lupus-and-multiple-myeloma-studies-as-it-shifts-development-focus\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4077","symbol_name":"互动媒体与服务","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/11/48873824/cartesian-pauses-lupus-and-multiple-myeloma-studies-as-it-shifts-development-focus","article_id":"2583685787","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/14/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/48873824/cartesian-pauses-lupus-and-multiple-myeloma-studies-as-it-shifts-development-focus","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2583685787","pubTimestamp":1763143320,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Cartesian Therapeutics, Inc.  on Friday shared initial data from the ongoing Phase 2 open-label trial of Descartes-08, its lead cell therapy candidate, for systemic lupus erythematosus .SLE is a chronic autoimmune disease where the body’s immune system attacks healthy tissues and organs, causing inflammation in various parts of the body, including joints, skin, kidneys, and the brain.Initial data reported a significant reduction in disease activity following initial Descartes-08 treatment, with 100% of participants who reached Month 3 follow-up (n=3) achieving Lupus Low Disease Activity State response.Disease remission was seen in 2 out of 3 participants at Month 3.At this time, Cartesian plans to pause further development of Descartes-08 in SLE, including enrollment in the Phase 2 trial, to prioritize the opportunities in myasthenia gravis, currently in Phase 3, and myositis.Cartesian announced the planned expansion of Descartes-08 into myositis.In this trial, no significant adverse e","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4077":"互动媒体与服务","RNAC":"Cartesian Therapeutics","BK4139":"生物科技","SLE":"Super League Gaming Inc."},"translate_title":"Cartesian暂停狼疮和多发性骨髓瘤研究，以转移开发重点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLE":1,"RNAC":1},"content_text":"Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Friday shared initial data from the ongoing Phase 2 open-label trial of Descartes-08, its lead cell therapy candidate, for systemic lupus erythematosus (SLE).\nSLE is a chronic autoimmune disease where the body’s immune system attacks healthy tissues and organs, causing inflammation in various parts of the body, including joints, skin, kidneys, and the brain.\nInitial data reported a significant reduction in disease activity following initial Descartes-08 treatment, with 100% of participants who reached Month 3 follow-up (n=3) achieving Lupus Low Disease Activity State response.\nAlso Read: AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate\nDisease remission was seen in 2 out of 3 participants at Month 3.\nAt this time, Cartesian plans to pause further development of Descartes-08 in SLE, including enrollment in the Phase 2 trial, to prioritize the opportunities in myasthenia gravis, currently in Phase 3, and myositis.\nCartesian announced the planned expansion of Descartes-08 into myositis.\nThe company plans to initiate an adaptive clinical trial design, which provides a potential opportunity for a single pivotal trial planned to commence in the first half of 2026.\nThe Phase 2 trial in myositis will assess Descartes-08 versus placebo administered as six weekly outpatient infusions without preconditioning chemotherapy in up to 50 patients with moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome.\nThe company plans to file an investigational new drug application (IND) for this trial by the end of 2025.\nThe company also reported results from the Phase 1 dose escalation trial of outpatient administration of Descartes-15 in patients with multiple myeloma.\nIn this trial, no significant adverse events or dose-limiting toxicities were reported in any participants (n=3). The only Descartes-15-related adverse event was a grade 2 hypotension occurring after the first two infusions.\nCartesian plans to pause the development of Descartes-15 to prioritize opportunities for Descartes-08 in MG and myositis.\nFollowing the pause in development of Descartes-15 in multiple myeloma and Descartes-08 in SLE, the company expects current cash resources to support planned operations through mid-2027.\nPrice Action: RNAC stock was trading higher by 4.91% to $7.585 at last check Friday.\nRead Next:\nImage via Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583685787","isCrawlerRequest":true}